Drug intelligence / Profile preview

YO-2

Development stage: Preclinical
Lead developer: Kobe Gakuin University
Modality: Small Molecules

Overview

YO-2 is a **selective plasmin inhibitor**, specifically categorized among novel dipeptide-based active site-directed inhibitors. Its chemical structure is N-(trans-4-aminomethylcyclohexanecarbonyl)-l-Tyr(O-picolyl)-NH-octyl. YO-2 displays potent inhibition of plasmin and has been shown to induce apoptosis in thymocytes, attributed to its hydrophobic C-terminal structure[1][2]. The mechanism includes blocking plasmin activity and is associated with increased caspase-3-like activity and DNA fragmentation in cellular apoptosis assays.

Other names: YO 2 compoundYO2 compoundYO-2 compound

Targets

KLKB1 (Plasma kallikrein)PLG (Plasminogen)PLAU (uPA)

Beyond the preview

Go deeper on YO-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YO-2.

Explore the full profile